Researchers are testing more drug combinations than ever before, and the most promising AI-tested combo this week managed to keep lung function at nearly 70% — a meaningful target for people living with IPF (a condition where the lungs slowly scar over time).
FVC = how much air your lungs can push out. Higher % = healthier lungs. A typical IPF patient starts around 50–60%.
This is a computer model result — not a prescription. Always talk to your doctor before changing anything.
This week the IPF research world is buzzing around three big themes: helping the lung's own lining cells repair themselves, understanding how scar-forming cells (called fibroblasts) behave, and exploring whether treatments that clear out old damaged cells (senolytics) might slow the disease. Researchers in Russia, China, and across Asia are publishing heavily right now, which means more global eyes are on this disease than ever before. That is genuinely good news for patients everywhere.
The AI tested a seven-drug combination and reached an FVC (a measure of how much air your lungs can hold and push out) of 69.5%. To put that simply: healthy lungs score around 100%, so holding steady near 70% means slowing the scarring significantly. The combo included familiar drugs like pirfenidone plus newer ideas like senolytic therapy (clearing out worn-out cells) and WNT pathway boosters (signals that help tissue heal).
One question to ask your lung doctor at your next visit: "Are there any clinical trials near me that combine my current antifibrotic medication with a senolytic or cell-repair drug?"